Literature DB >> 11229419

Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese.

Z S Lee1, J A Critchley, B Tomlinson, R P Young, G N Thomas, C S Cockram, T Y Chan, J C Chan.   

Abstract

The metabolic syndrome is characterized by a clustering of cardiovascular risk factors including type 2 diabetes mellitus, hypertension, dyslipidemia, and obesity. Elevated plasma insulin and urinary norepinephrine (noradrenaline) and reduced urinary epinephrine (adrenaline) excretion are associated with obesity in Caucasian populations. We examined the interrelationships between obesity, plasma insulin, and urinary catecholamine excretion in Chinese subjects with various components of the metabolic syndrome. A total of 577 Chinese subjects (aged 38 +/- 10 years; 68% with type 2 diabetes mellitus, hypertension, dyslipidemia, obesity, and/or albuminuria and 32% healthy subjects) were studied, all of whom had a plasma creatinine less than 150 micromol/L. The blood pressure, height, weight, waist and hip circumference, and fasting plasma glucose, insulin, lipid, and creatinine levels were measured. A 24-hour urine sample was collected for measurement of albumin and catecholamine excretion. The body mass index (BMI) and waist circumference were used as measures of general and central obesity, respectively. The insulin resistance index was estimated by the calculated product of fasting plasma insulin and glucose concentrations. Patients with an increasing number of components of the metabolic syndrome (type 2 diabetes mellitus, hypertension, dyslipidemia, obesity, and/or albuminuria) were more obese, hyperglycemic, dyslipidemic, and albuminuric and had higher blood pressure, plasma insulin, insulin resistance indices, and 24-hour urinary norepinephrine excretion but lower urinary epinephrine output (all P < .005). Increasing quintiles of BMI in the whole population or waist circumference in both sexes were associated with increasing trends for adverse lipid profiles, plasma insulin, insulin resistance indices, and urinary norepinephrine excretion but a decreasing trend for urinary epinephrine output (all P < .001). There were close associations between age, obesity, blood pressure, fasting plasma glucose, lipid, insulin, insulin resistance indices, and urinary catecholamine excretion. Using stepwise multiple regression analysis (all P < .001), 34% of the variability of the BMI and 45% of that of the waist circumference were independently related to gender (waist higher in males and BMI higher in females), increased plasma insulin, triglyceride, and urinary norepinephrine excretion, and decreased high-density lipoprotein (HDL) cholesterol and urinary epinephrine output. In Chinese subjects with different manifestations of the metabolic syndrome, hyperinsulinemia, insulin resistance, elevated norepinephrine, and reduced epinephrine excretion were closely associated with general and central obesity. Based on these findings, we postulate that complex interactions between the insulin and sympathoadrenal systems may lead to the development of obesity and the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229419     DOI: 10.1053/meta.2001.19502

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  36 in total

Review 1.  Obesity and adipokines: effects on sympathetic overactivity.

Authors:  Michael M Smith; Christopher T Minson
Journal:  J Physiol       Date:  2012-02-20       Impact factor: 5.182

Review 2.  Neurocardiology: therapeutic implications for cardiovascular disease.

Authors:  David S Goldstein
Journal:  Cardiovasc Ther       Date:  2010-11-25       Impact factor: 3.023

Review 3.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Mediators of sympathetic activation in metabolic syndrome obesity.

Authors:  Nora E Straznicky; Nina Eikelis; Elisabeth A Lambert; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

5.  Association of depressive and anxiety symptoms with 24-hour urinary catecholamines in individuals with untreated high blood pressure.

Authors:  Nicola J Paine; Lana L Watkins; James A Blumenthal; Cynthia M Kuhn; Andrew Sherwood
Journal:  Psychosom Med       Date:  2015 Feb-Mar       Impact factor: 4.312

6.  Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.

Authors:  Chiang-shan R Li; Marc N Potenza; Dianne E Lee; Beata Planeta; Jean-Dominique Gallezot; David Labaree; Shannan Henry; Nabeel Nabulsi; Rajita Sinha; Yu-Shin Ding; Richard E Carson; Alexander Neumeister
Journal:  Neuroimage       Date:  2013-10-10       Impact factor: 6.556

Review 7.  Posttraumatic stress disorder: A metabolic disorder in disguise?

Authors:  Vasiliki Michopoulos; Aimee Vester; Gretchen Neigh
Journal:  Exp Neurol       Date:  2016-05-28       Impact factor: 5.330

Review 8.  Metabolic Factors Determining the Susceptibility to Weight Gain: Current Evidence.

Authors:  Tim Hollstein; Paolo Piaggi
Journal:  Curr Obes Rep       Date:  2020-06

Review 9.  Diabetes and its comorbidities--where East meets West.

Authors:  Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

10.  Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects.

Authors:  Nora E Straznicky; Elisabeth A Lambert; Paul J Nestel; Mariee T McGrane; Tye Dawood; Markus P Schlaich; Kazuko Masuo; Nina Eikelis; Barbora de Courten; Justin A Mariani; Murray D Esler; Florentia Socratous; Reena Chopra; Carolina I Sari; Eldho Paul; Gavin W Lambert
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.